GRCE
ACHAT TOTAL: 100 000 titres (~214 000,00 $ US)
- Insiders
- Kohli Prashant
- Total bought
- $214,000
- Total sold
- —
- Last activity
- 2026-09-09
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-10
GRCE presents a deeply conflicted profile: while the insider cluster buy following a clean FDA Type A meeting and a $10M placement extending runway to 2028 signals moderate near-term catalytic potential (score: 65), the…
The first sentence of the analysis written for GRCE on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 8.099 | 11.768 | 14.258 | 8.587 | 13.967 | |
| Quick Ratio | 8.099 | 11.768 | 14.258 | 8.587 | 13.967 | |
| Solvency Ratio | -2.823 | -2.529 | -1.504 | -5.123 | -0.603 | |
| Cash Ratio | 7.911 | 11.468 | 13.661 | 8.172 | 9.306 | |
| Price To Earnings Ratio | -9.851 | -2.018 | -1.645 | -0.390 | -1.490 | |
| Price To Earnings Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Forward Price To Earnings Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Price To Earnings Diluted Ratio | -9.851 | -2.018 | -1.645 | -0.390 | -1.490 | |
| Price To Earnings Diluted Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Price To Book Ratio | 1.196 | 0.414 | 0.465 | 0.329 | 0.171 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -8.619 | -1.849 | -2.322 | -1.405 | -1.072 | |
| Price To Operating Cash Flow Ratio | -8.619 | -1.849 | -2.326 | -1.406 | -1.072 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.006 | 0.002 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.007 | 0.003 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.007 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.043 | 1.081 | 1.187 | 1.164 | 1.188 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.133 | -7.722 | -7.324 | -4.665 | -5.287 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.002 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -154.748 | -176.512 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -212.173 | -165.712 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -32.810 | -58.420 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -560.591 | -936.059 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -560.591 | -936.059 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.372 | -0.229 | -0.369 | 0.204 | 0.603 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 8.099 | ▼-3.669 | ▼-3.237 |
| Quick Ratio | 8.099 | ▼-3.669 | ▼-3.237 |
| Solvency Ratio | -2.823 | ▼-0.294 | ▼-0.306 |
| Cash Ratio | 7.911 | ▼-3.557 | ▼-2.193 |
| Price To Earnings Ratio | -9.851 | ▼-7.833 | ▼-6.772 |
| Price To Earnings Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Forward Price To Earnings Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Price To Earnings Diluted Ratio | -9.851 | ▼-7.833 | ▼-6.772 |
| Price To Earnings Diluted Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Price To Book Ratio | 1.196 | ▲0.783 | ▲0.681 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -8.619 | ▼-6.770 | ▼-5.566 |
| Price To Operating Cash Flow Ratio | -8.619 | ▼-6.770 | ▼-5.565 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.002 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.002 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.043 | ▼-0.038 | ▼-0.089 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.133 | ▲3.590 | ▲1.693 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲66.252 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲75.577 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲18.246 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲299.330 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲299.330 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.372 | ▼-5.143 | ▼-4.340 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $76.4M | $27.6M | $28.7M | $22.4M | $18.5M | |
| Enterprise value | $59.5M | $5.4M | $5.7M | -$5.0M | -$11.6M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.71x | -0.36x | -0.46x | 0.32x | 0.67x | |
| EV / Free cash flow | -6.71x | -0.36x | -0.46x | 0.31x | 0.67x | |
| EV / EBITDA | -5.37x | -0.23x | -0.37x | 0.20x | 0.60x | |
| Net debt / EBITDA | 1.53x | 0.93x | 1.50x | 1.12x | 1.57x | |
| Current ratio | 8.10x | 11.77x | 14.26x | 8.59x | 13.97x | |
| Income quality | 1.14x | 1.56x | 0.96x | 0.38x | 1.75x | |
| Graham net-net | $1 | $1 | $1 | $2 | $4 | |
| Tax burden | 82.1% | 74.9% | 87.5% | 81.6% | 93.8% | |
| Interest burden | 85.7% | 76.5% | 129.2% | 284.8% | 68.2% | |
| Working capital | $15.2M | $20.8M | $22.3M | $25.9M | $42.3M | |
| Invested capital | $64.5M | $70.1M | $71.6M | $75.7M | $125.4M | |
| Return on assets | -11.7% | -18.9% | -23.8% | -72.5% | -9.5% | |
| Operating ROA | -16.0% | -32.7% | -22.9% | -67.9% | -18.8% | |
| Return on tangible assets | -44.8% | -60.0% | -72.6% | -192.2% | -26.8% | |
| Return on equity | -12.2% | -20.5% | -28.2% | -84.4% | -11.3% | |
| Return on invested capital | -14.1% | -25.4% | -21.3% | -76.0% | -14.6% | |
| Return on capital employed | -17.2% | -33.9% | -24.4% | -93.2% | -15.5% | |
| Earnings yield | -10.2% | -49.4% | -60.8% | -256.4% | -66.4% | |
| Free cash flow yield | -11.6% | -54.1% | -43.1% | -71.2% | -93.2% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.2% | -0.1% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 200.0% | 13.7% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 73.9% | 68.4% | 67.2% | 62.3% | 64.4% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+177.4%EV / Sales n/aEV / EBITDA ▼-2250.6%EV / Op. cash flow ▼-6.341Earnings yield ▲+0.392
Profitability
Return on equity ▲+0.083Return on assets ▲+0.072Return on invested capital ▲+0.113Return on capital employed ▲+0.167Operating ROA ▲+0.167Income quality ▼-0.420Tax burden ▲+0.071
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-3.669Net debt / EBITDA ▲+0.601Working capital ▼-5548000.000Invested capital ▼-5555000.000Intangibles / Total assets ▲+0.055
Change over 5 years
Valuation
Market cap ▲+313.6%EV / Sales n/aEV / EBITDA ▼-990.6%EV / Op. cash flow ▼-7.376Earnings yield ▲+0.562
Profitability
Return on equity ▼-0.009Return on assets ▼-0.022Return on invested capital ▲+0.005Return on capital employed ▼-0.016Operating ROA ▲+0.028Income quality ▼-0.617Tax burden ▼-0.117
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.868Net debt / EBITDA ▼-0.034Working capital ▼-27037000.000Invested capital ▼-60852000.000Intangibles / Total assets ▲+0.096
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-03 Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C.
- 2026-08-13 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.
- 2026-08-04 Grace Therapeutics Announces $10 Million Private Placement Expected gross proceeds anticipated to extend the Company''s cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company''s cash runway to the end of calendar 2028
- 2026-07-28 Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026.
- 2026-07-23 Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report)''s share price fell 2.5% on Wednesday. The stock traded as low as $2.36 and last traded at $2.37. 103,999 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 223,157 shares. The stock had previously closed at $2.43. Analysts Set
- 2026-06-18 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026.
- 2026-06-11 GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or "the Company") (NASDAQ: GRCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.